Abstract:Background The cyclic adenosine monophosphate/phosphodiesterase 4 ( cAMP/PDE4) pathway is involved in inflammation and immune regulation; however, the effect of cAMP/PDE4 on immune infiltration and immune evasion in lung adenocarcinoma (LUAD) remains unclear. Methods CBioPortal, which is the The Cancer Genome Atlas (TCGA) online database, and the Kaplan Meier plotter were used to analyze the association between genes and the prognosis of TCGA-LUAD. Tumor Immune Estimation Resource (TIMER) was used to analyze the association between gene expression and immune infiltration. The Genecards database was used to identify the transcription factors of related genes. The lung adenocarcinoma cell line H1299 and A549 were treated with cAMP pathway drugs. Flow cytometry and qRT-PCR were used to detect the PD-L1 protein and gene expression, respectively. A one-way analysis of variance with Tukey’s post-hoc test or a Student’s t-test were used. Results It was found that PDE4B and CREB1, which are downstream genes of the cAMP/PDE4 axis, were differentially expressed in LUAD and adjacent tissues and are correlated with the prognosis and immune infiltration of LUAD. In the CBioPortal database, cAMP pathway genes are closely related to programmed cell death-ligand 1 (PD-L1) expression in TCGA-LUAD. The protein-protein interaction revealed that there was a direct interaction between CREB1/CREBBP, which are the downstream molecules of the cAMP/PDE4 axis, and MYC; additionally, MYC was predicted to bind to the PD-L1 transcription site and regulate PD-L1 expression. CREB1 was also predicted to transcriptionally bind to both MYC and PD-L1. These results predicted the interaction network of cAMP/PDE4/CREB1/CREBP/MYC/PD-L1, and the core factor may be related to MYC. In the cell experiment, forskolin (an adenylate cyclase activator) and zardaverine (a PDE4 inhibitor) enhance the cAMP pathway and decrease PD-L1 expression, while SQ2253 (an adenylate cyclase inhibitor) inhibits the cAMP pathway and increases PD-L1 expression of the LUAD cell lines H1299 and A549, and MYC regulation by these drugs was positively correlated with PD-L1 regulation, which verified the regulation of the cAMP/PDE4 pathway on MYC and PD-L1. Conclusions This study showed that the cAMP/PDE4 pathway may play an important role in PD-L1 regulation and immune infiltration in LUAD.

Potential Anti-tumor Properties of PDIA4 in Lung Adenocarcinoma

IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma

IMP4 Silencing Inhibits the Malignancy of Lung Adenocarcinoma Via ERK Pathway

High Expression of PDIA4 Promotes Malignant Cell Behavior and Predicts Reduced Survival in Cervical Cancer.

MicroRNA-mediated high expression of PDIA3 was correlated with poor prognosis of patients with LUAD

A Novel Pro-Apoptosis Gene Pnas4 That Induces Apoptosis in A549 Human Lung Adenocarcinoma Cells and Inhibits Tumor Growth in Mice

piR-hsa-211106 Inhibits the Progression of Lung Adenocarcinoma Through Pyruvate Carboxylase and Enhances Chemotherapy Sensitivity

Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer

Lung Adenocarcinoma Expression of the Aryl Hydrocarbon Receptor Promotes PD-L1 and Immune Suppression

Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy

AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3

HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma

Peptidyl-prolyl Isomerase F As a Prognostic Biomarker Associated with Immune Infiltrates and Mitophagy in Lung Adenocarcinoma

Knockdown of CDK5 Down-Regulates PD-L1 Via the Ubiquitination-Proteasome Pathway and Improves Antitumor Immunity in Lung Adenocarcinoma

The Aryl Hydrocarbon Receptor Controls IFNγ-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma

Characteristics of the immune microenvironment associated with RRM2 expression and its application to PD-L1/PD-1 inhibitors in lung adenocarcinoma

Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells

PTEN Inhibits Cell Proliferation, Promotes Cell Apoptosis, and Induces Cell Cycle Arrest via Downregulating the PI3K/AKT/hTERT Pathway in Lung Adenocarcinoma A549 Cells

IL-1β-Mediated Up-Regulation of WT1D Via Mir-144-3p and Their Synergistic Effect with NF-κB/COX-2/HIF-1α Pathway on Cell Proliferation in LUAD

The Mechanism of ABL1 Upregulating the Expression of PD-L1 and the Therapeutic Effect of PD-L1 and STAT3 Inhibitors in Lung Adenocarcinoma.

P2.01-050 Clinicopathological Characteristics of PD-L1 Expression in Lung Adenocarcinoma: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy